Collagen bioavailability refers to whether a collagen peptide survives digestion and reaches the bloodstream intact, and the answer depends entirely on the specific peptide, not on collagen as a general category.
It’s a reasonable thing to wonder: you swallow a scoop of collagen powder, and somewhere between your stomach and your skin, is anything of it surviving the trip? This isn’t a philosophical question. It’s a measurable one, and researchers have tested it directly.
The Study That First Confirmed Collagen Bioavailability
In 2011, Shigemura and colleagues published a study in Food Chemistry identifying a specific collagen-derived dipeptide, hydroxyprolyl-glycine, in human blood following oral collagen peptide intake.¹ This was a meaningful finding because it moved collagen peptides from “something you swallowed” to “something detectable in circulation,” giving direct evidence that at least some collagen fragments survive the digestive process intact rather than being fully broken down into individual amino acids like ordinary dietary protein.
A separate, related body of research has focused on a different dipeptide, prolyl-hydroxyproline (Pro-Hyp), which has also been measured directly in human blood after oral intake and appears to be one of the most abundant collagen-derived peptides found in circulation.² Together, these findings form the foundation for how researchers understand collagen bioavailability today: certain small peptide fragments, not collagen protein as a whole, are what reach the bloodstream.
Peptide Size and Collagen Bioavailability
Collagen bioavailability isn’t a fixed property of “collagen” as an ingredient. It depends heavily on peptide size. Larger fragments are more likely to be broken down further during digestion into individual amino acids, which strips away any specific, targeted signaling. Smaller, more precisely processed dipeptides and tripeptides are far more likely to survive intact.³ This is a large part of why the specific hydrolysis process used to manufacture a collagen ingredient matters so much, since it directly determines what size peptides end up in the finished product.
What Happens After Collagen Peptides Reach the Blood
Confirming that a peptide reaches the bloodstream is the first step, but researchers have also studied what happens next. Laboratory research has found that collagen-derived dipeptides can interact directly with fibroblasts and related cells, stimulating processes like cell proliferation and hyaluronic acid synthesis.⁴ A separate study on tendon cells found that a related dipeptide activated a specific receptor pathway involving beta-1 integrin, providing a direct mechanism for how an absorbed peptide can influence collagen-producing cells once it arrives at its target tissue.⁵
What to Look For: Collagen Bioavailability, Not Just Ingredients
Collagen bioavailability isn't something you can tell by reading a front-of-package claim. It has to be confirmed the way Shigemura's team confirmed it: by testing whether a specific peptide, in blood, in the hours after intake. Very few products on the market have gone through this kind of testing for their exact formulation. A brand can hydrolyze collagen, sell it as "collagen peptides," and never once verify whether the fragments produced are small enough to survive digestion, let alone whether any of it reaches circulation in a form fibroblasts or tendon cells can recognize and respond to.
This is why a product's evidence should match its claim at every step, not just the first one. Confirming absorption (peptides detected in blood) is different from confirming activity (those peptides triggering a measurable response, like the fibroblast proliferation Ohara's team found, or the receptor-level signaling seen in tendon cells). A collagen ingredient can clear one hurdle without clearing the other, which is exactly why patented, clinically studied peptides publish data on both steps rather than one.
This is the standard Monna holds every ingredient to before it goes into a formula: not an assumption that collagen works, but published evidence that the specific peptide reaches circulation, and a separate line of evidence that the peptide does something once it gets there.